Whole blood gene expression and interleukin-6 levels

Genomics

Volumn 104, Issue 6, 2014, Pages 490-495

  Lin, Honghuang ^a,b   Joehanes, Roby ^b,c,d   Pilling, Luke C ^e   Dupuis, Josée ^b,g   Lunetta, Kathryn L ^b,g   Ying, Sai Xia ^c   Benjamin, Emelia J ^a,b,g   Hernandez, Dena ^f   Singleton, Andrew ^f   Melzer, David ^e   Munson, Peter J ^b,c,d   Levy, Daniel ^b,d   Ferrucci, Luigi ^f   Murabito, Joanne M ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FRAMINGHAM HEART STUDY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e UNIVERSITY OF EXETER   (United Kingdom)

^f NATIONAL INSTITUTE ON AGING   (United States)

^g BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Epidemiology; Gene expression; Inflammation; Interleukin 6

Indexed keywords

CD135 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; JANUS KINASE; STAT PROTEIN; IL6 PROTEIN, HUMAN; TRANSCRIPTOME;

AGED; ARTICLE; ERYTHROCYTE; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MALE; SIGNAL TRANSDUCTION; BLOOD; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETICS;

GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; INTERLEUKIN-6; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 84919385246     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2014.10.003     Document Type: Article

References (63)

1. Kishimoto T. The biology of interleukin-6. Blood 1989, 74:1-10.
2. Packard R.R., Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin. Chem. 2008, 54:24-38.
3. Raschke S., Eckel J. Adipo-myokines: two sides of the same coin-mediators of inflammation and mediators of exercise. Mediat. Inflamm. 2013, 2013:320724.
4. Feghali C.A., Wright T.M. Cytokines in acute and chronic inflammation. Front. Biosci. 1997, 2:d12-d26.
5. Abeywardena M.Y., Leifert W.R., Warnes K.E., Varghese J.N., Head R.J. Cardiovascular biology of interleukin-6. Curr. Pharm. Des. 2009, 15:1809-1821.
6. Schuett H., Luchtefeld M., Grothusen C., Grote K., Schieffer B. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb. Haemost. 2009, 102:215-222.
7. Akira S., Hirano T., Taga T., Kishimoto T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J. 1990, 4:2860-2867.
8. Brubaker A.L., Palmer J.L., Kovacs E.J. Age-related dysregulation of inflammation and innate immunity: lessons learned from rodent models. Aging Dis. 2011, 2:346-360.
9. Schnabel R.B., Yin X., Larson M.G., Yamamoto J.F., Fontes J.D., Kathiresan S., Rong J., Levy D., Keaney J.F., Wang T.J., Murabito J.M., Vasan R.S., Benjamin E.J. Multiple inflammatory biomarkers in relation to cardiovascular events and mortality in the community. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1728-1733.
10. Vasan R.S., Sullivan L.M., Roubenoff R., Dinarello C.A., Harris T., Benjamin E.J., Sawyer D.B., Levy D., Wilson P.W., D'Agostino R.B., Framingham Heart S. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003, 107:1486-1491.
11. Weidle U.H., Klostermann S., Eggle D., Kruger A. Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer. Cancer Genomics Proteomics 2010, 7:287-302.
12. Bertoni A.G., Burke G.L., Owusu J.A., Carnethon M.R., Vaidya D., Barr R.G., Jenny N.S., Ouyang P., Rotter J.I. Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2010, 33:804-810.
13. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
14. Chun H.Y., Chung J.W., Kim H.A., Yun J.M., Jeon J.Y., Ye Y.M., Kim S.H., Park H.S., Suh C.H. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol. 2007, 27:461-466.
15. Porta C., De Amici M., Quaglini S., Paglino C., Tagliani F., Boncimino A., Moratti R., Corazza G.R. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann. Oncol. 2008, 19:353-358.
16. Luc G., Bard J.M., Juhan-Vague I., Ferrieres J., Evans A., Amouyel P., Arveiler D., Fruchart J.C., Ducimetiere P., Group P.S. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1255-1261.
17. Weaver J.D., Huang M.H., Albert M., Harris T., Rowe J.W., Seeman T.E. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 2002, 59:371-378.
18. Schaap L.A., Pluijm S.M., Deeg D.J., Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am. J. Med. 2006, 119:526. e9-17.
19. Cesari M., Penninx B.W., Pahor M., Lauretani F., Corsi A.M., Rhys W.G., Guralnik J.M., Ferrucci L. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J. Gerontol. A Biol. Sci. Med. Sci. 2004, 59:242-248.
20. Ferrucci L., Harris T.B., Guralnik J.M., Tracy R.P., Corti M.C., Cohen H.J., Penninx B., Pahor M., Wallace R., Havlik R.J. Serum IL-6 level and the development of disability in older persons. J. Am. Geriatr. Soc. 1999, 47:639-646.
21. Cappola A.R., Xue Q.L., Ferrucci L., Guralnik J.M., Volpato S., Fried L.P. Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J. Clin. Endocrinol. Metab. 2003, 88:2019-2025.
22. Ershler W.B., Keller E.T. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu. Rev. Med. 2000, 51:245-270.
23. Figaro M.K., Kritchevsky S.B., Resnick H.E., Shorr R.I., Butler J., Shintani A., Penninx B.W., Simonsick E.M., Goodpaster B.H., Newman A.B., Schwartz A.V., Harris T.B. Diabetes, inflammation, and functional decline in older adults: findings from the Health, Aging and Body Composition (ABC) study. Diabetes Care 2006, 29:2039-2045.
24. Cheng C.C., Hsueh C.M., Chen C.Y., Chen T.H., Hsu S.L. Interleukin-6 upregulates paraoxonase 1 gene expression via an AKT/NF-kappaB-dependent pathway. Biochem. Biophys. Res. Commun. 2013, 437:55-61.
25. Lai H.S., Lin W.H., Lai S.L., Lin H.Y., Hsu W.M., Chou C.H., Lee P.H. Interleukin-6 mediates angiotensinogen gene expression during liver regeneration. PLoS ONE 2013, 8:e67868.
26. Wrighting D.M., Andrews N.C. Interleukin-6 induces hepcidin expression through STAT3. Blood 2006, 108:3204-3209.
27. Grassl C., Luckow B., Schlondorff D., Dendorfer U. Transcriptional regulation of the interleukin-6 gene in mesangial cells. J. Am. Soc. Nephrol. 1999, 10:1466-1477.
28. Ferrari S.L., Ahn-Luong L., Garnero P., Humphries S.E., Greenspan S.L. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J. Clin. Endocrinol. Metab. 2003, 88:255-259.
29. Dawber T.R., Kannel W.B., Lyell L.P. An approach to longitudinal studies in a community: the Framingham Study. Ann. N. Y. Acad. Sci. 1963, 107:539-556.
30. Feinleib M., Kannel W.B., Garrison R.J., McNamara P.M., Castelli W.P. The Framingham Offspring Study. Design and preliminary data. Prev. Med. 1975, 4:518-525.
31. Kannel W.B., Feinleib M., McNamara P.M., Garrison R.J., Castelli W.P. An investigation of coronary heart disease in families. The Framingham offspring study. Am. J. Epidemiol. 1979, 110:281-290.
32. Fontes J.D., Yamamoto J.F., Larson M.G., Wang N., Dallmeier D., Rienstra M., Schnabel R.B., Vasan R.S., Keaney J.F., Benjamin E.J. Clinical correlates of change in inflammatory biomarkers: the Framingham Heart Study. Atherosclerosis 2013, 228:217-223.
33. Joehanes R., Ying S., Huan T., Johnson A.D., Raghavachari N., Wang R., Liu P., Woodhouse K.A., Sen S.K., Tanriverdi K., Courchesne P., Freedman J.E., O'Donnell C.J., Levy D., Munson P.J. Gene expression signatures of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1418-1426.
34. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., Speed T.P. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
35. Schnabel R.B., Lunetta K.L., Larson M.G., Dupuis J., Lipinska I., Rong J., Chen M.H., Zhao Z., Yamamoto J.F., Meigs J.B., Nicaud V., Perret C., Zeller T., Blankenberg S., Tiret L., Keaney J.F., Vasan R.S., Benjamin E.J. The relation of genetic and environmental factors to systemic inflammatory biomarker concentrations. Circ. Cardiovasc. Genet. 2009, 2:229-237.
36. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol. 1995, 57:289-300.
37. Cesari M., Penninx B.W., Pahor M., Lauretani F., Corsi A.M., Rhys Williams G., Guralnik J.M., Ferrucci L. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J. Gerontol. A: Biol. Med. Sci. 2004, 59:242-248.
38. Ferrucci L., Bandinelli S., Benvenuti E., Di Iorio A., Macchi C., Harris T.B., Guralnik J.M. Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. J. Am. Geriatr. Soc. 2000, 48:1618-1625.
39. Harries L.W., Hernandez D., Henley W., Wood A.R., Holly A.C., Bradley-Smith R.M., Yaghootkar H., Dutta A., Murray A., Frayling T.M., Guralnik J.M., Bandinelli S., Singleton A., Ferrucci L., Melzer D. Human aging is characterized by focused changes in gene expression and deregulation of alternative splicing. Aging Cell 2011, 10:868-878.
40. Habib G.M., Shi Z.Z., Cuevas A.A., Lieberman M.W. Identification of two additional members of the membrane-bound dipeptidase family. FASEB J. 2003, 17:1313-1315.
41. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:15545-15550.
42. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100:1532-1542.
43. Fricke B., Jarvis H.G., Reid C.D., Aguilar-Martinez P., Robert A., Quittet P., Chetty M., Pizzey A., Cynober T., Lande W.F., Mentzer W.C., During M., Winter S., Delaunay J., Stewart G.W. Four new cases of stomatin-deficient hereditary stomatocytosis syndrome: association of the stomatin-deficient cryohydrocytosis variant with neurological dysfunction. Br. J. Haematol. 2004, 125:796-803.
44. Figueroa D. The Diego blood group system: a review. Immunohematology 2013, 29:73-81.
45. Bishop D.F., Tchaikovskii V., Hoffbrand A.V., Fraser M.E., Margolis S. X-linked sideroblastic anemia due to carboxyl-terminal ALAS2 mutations that cause loss of binding to the beta-subunit of succinyl-CoA synthetase (SUCLA2). J. Biol. Chem. 2012, 287:28943-28955.
46. Nishimura R., Moriyama K., Yasukawa K., Mundy G.R., Yoneda T. Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells. J. Bone Miner. Res. 1998, 13:777-785.
47. Hobisch A., Eder I.E., Putz T., Horninger W., Bartsch G., Klocker H., Culig Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 1998, 58:4640-4645.
48. Ueda T., Bruchovsky N., Sadar M.D. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem. 2002, 277:7076-7085.
49. Yang L., Wang L., Lin H.K., Kan P.Y., Xie S., Tsai M.Y., Wang P.H., Chen Y.T., Chang C. Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem. Biophys. Res. Commun. 2003, 305:462-469.
50. van den Biggelaar A.H., Huizinga T.W., de Craen A.J., Gussekloo J., Heijmans B.T., Frolich M., Westendorp R.G. Impaired innate immunity predicts frailty in old age. The Leiden 85-plus study. Exp. Gerontol. 2004, 39:1407-1414.
51. Leng S.X., Yang H., Walston J.D. Decreased cell proliferation and altered cytokine production in frail older adults. Aging Clin. Exp. Res. 2004, 16:249-252.
52. Walston J., Fedarko N., Yang H., Leng S., Beamer B., Espinoza S., Lipton A., Zheng H., Becker K. The physical and biological characterization of a frail mouse model. J. Gerontol. A Biol. Sci. Med. Sci. 2008, 63:391-398.
53. Sikka G., Miller K.L., Steppan J., Pandey D., Jung S.M., Fraser C.D., Ellis C., Ross D., Vandegaer K., Bedja D., Gabrielson K., Walston J.D., Berkowitz D.E., Barouch L.A. Interleukin 10 knockout frail mice develop cardiac and vascular dysfunction with increased age. Exp. Gerontol. 2013, 48:128-135.
54. Ko F., Yu Q., Xue Q.L., Yao W., Brayton C., Yang H., Fedarko N., Walston J. Inflammation and mortality in a frail mouse model. Age (Dordr) 2012, 34:705-715.
55. Worns M.A., Victor A., Galle P.R., Hohler T. Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels-a study in twins. Genes Immun. 2006, 7:600-605.
56. Reich D., Patterson N., Ramesh V., De Jager P.L., McDonald G.J., Tandon A., Choy E., Hu D., Tamraz B., Pawlikowska L., Wassel-Fyr C., Huntsman S., Waliszewska A., Rossin E., Li R., Garcia M., Reiner A., Ferrell R., Cummings S., Kwok P.Y., Harris T., Zmuda J.M., Ziv E., Health A., Body Composition S. Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. Am. J. Hum. Genet. 2007, 80:716-726.
57. Naitza S., Porcu E., Steri M., Taub D.D., Mulas A., Xiao X., Strait J., Dei M., Lai S., Busonero F., Maschio A., Usala G., Zoledziewska M., Sidore C., Zara I., Pitzalis M., Loi A., Virdis F., Piras R., Deidda F., Whalen M.B., Crisponi L., Concas A., Podda C., Uzzau S., Scheet P., Longo D.L., Lakatta E., Abecasis G.R., Cao A., Schlessinger D., Uda M., Sanna S., Cucca F. A genome-wide association scan on the levels of markers of inflammation in Sardinians reveals associations that underpin its complex regulation. PLoS Genet. 2012, 8:e1002480.
58. Palmer C., Diehn M., Alizadeh A.A., Brown P.O. Cell-type specific gene expression profiles of leukocytes in human peripheral blood. BMC Genomics 2006, 7:115.
59. Feezor R.J., Baker H.V., Mindrinos M., Hayden D., Tannahill C.L., Brownstein B.H., Fay A., MacMillan S., Laramie J., Xiao W., Moldawer L.L., Cobb J.P., Laudanski K., Miller-Graziano C.L., Maier R.V., Schoenfeld D., Davis R.W., Tompkins R.G. Inflammation, L.-S.C.R.P. host response to injury, whole blood and leukocyte RNA isolation for gene expression analyses. Physiol. Genomics 2004, 19:247-254.
60. Shen-Orr S.S., Tibshirani R., Khatri P., Bodian D.L., Staedtler F., Perry N.M., Hastie T., Sarwal M.M., Davis M.M., Butte A.J. Cell type-specific gene expression differences in complex tissues. Nat. Methods 2010, 7:287-289.
61. Adam O., Lavall D., Theobald K., Hohl M., Grube M., Ameling S., Sussman M.A., Rosenkranz S., Kroemer H.K., Schafers H.J., Bohm M., Laufs U. Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. J. Am. Coll. Cardiol. 2010, 55:469-480.
62. Matkovich S.J., Zhang Y., Van Booven D.J., Dorn G.W. Deep mRNA sequencing for in vivo functional analysis of cardiac transcriptional regulators: application to Galphaq. Circ. Res. 2010, 106:1459-1467.
63. Danesh J., Kaptoge S., Mann A.G., Sarwar N., Wood A., Angleman S.B., Wensley F., Higgins J.P., Lennon L., Eiriksdottir G., Rumley A., Whincup P.H., Lowe G.D., Gudnason V. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 2008, 5:e78.